We also evaluated change in weight during the active weight-loss maintenance intervention (6 M- 0-M)) and four other secondary outcoM- 0-Mhange in stress, depression, insoM- 0-Mquandty ofourfe frotherM to 12 M) usecondarysame moutcomes prochange as for the prinary outcome analystress
Other independent baseline variables in the analysis were age (over/under 40 years), seasonality (from the SPAQ), initial, middle and late insomnia, quality of sleep, feeling tired after waking (from the BNSQ), serum total cholesterol levels, current smoking, physical training, and consumption of alcoholic beverages (from the FINRISK questionnaire).
Restless legs syndrome (RLS) has been associated with insomnia, decreased quality of life, and increased morbidity and mortality in end-stage renal disease.
STUDY OBJECTIVES: To evaluate 6 months' eszopiclone treatment upon patient-reported sleep, fatigue and sleepiness, insomnia severity, quality of life, and work limitations.
From the BNSQ, following variables were chosen: initial, middle, and late insomnia, and quality of sleep.
3 RLS is frequently associated with insomnia, impaired quality of life and depression.
Secondary outcomes were change in depression, stress, insomnia, and quality of life.
Scientific evidence has demonstrated that intensive education programs (between 6 and 17 sessions) improve pain symptoms, fatigue, insomnia and quality of life.
Although this multifaceted structure of the RIS indicates its potential for differential assessment of different dimensions of insomnia (sleep quality, sleep quantity, focus on insomnia and medication intake) it should be noted that the RIS has been developed and validated as a single scale and should also be primarily used so.
Similarly, no significant difference was observed between treatments among the secondary outcomes of change from 0-M to 12 M in depression, stress, insomnia, or quality of life (all p >.5, see Table 4) (LCL = lower confidence limit, UCL = upper confidence limit) We obtained results similar to the primary outcome analysis above when BMI was substituted for weight in the primary outcome model.
Trazodone, a commonly used off-label drug for insomnia, improves sleep quality and sleep continuity but carries significant risks.
